Ifosfamide-induced hyperpigmentation
β Scribed by S. M. Yule; A. D. Pearson; A. W. Craft; Mary E. Teresi; Daryl J. Murry
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 162 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
We read with interest the article on ifosfamide-induced hyperpigmentation by Teresi et al.' In our experience, this is a widespread, if underreported phenomenon.
In Newcastle, United Kingdom, children with nonmetastatic soft tissue sarcomas are initially treated with five courses of ifosfamide (IF) and etoposide before reassessment and local therapy. IF (9 g/m') is administered as a continuous infusion over 72 hours. Hydration (3 I/m2/day) containing MESNA (3 g/m2/day) is given concurrently and continued for 12 hours after completion of the IF infusion. Etoposide (200 mg/m2) is given on each of these 3 days. We have treated seven children with this regimen during the last 18 months (Table 1).
Among this small group, hyperpigmentation developed in five (71%). In one case, this was only noticeable under an occlusive dressing and faded rapidly upon its removal. The most common sites were the dorsal and plantar surfaces of the hands and feet. Hyperpigmentation of the scrotum occurred in two boys. In severe cases, large areas of the trunk were affected. Only one child had nail involvement. The onset of pigmentation was variable but appeared to be more rapid among children of mixed race. A generalized increase in pigmentation was noted in one child after a single course of treatment. Persistence is variable-Patient 3 remains hyperpigmented 6 months after completing 16 courses of IF. In other cases, hyperpigmentation faded despite continued treatment with IF.
Teresi and colleagues speculate that IF-induced hyperpigmentation may be linked to concurrent renal impairment, implying that it may be secondary to reduced drug or metabolite clearance and/or altered metabolism. We recently described the pharmacokinetics and metabolism of continuousinfusion IF in 17 children, including those described here.' These data do not suggest altered pharmacokinetics or metabolism in the hyperpigmented group. Chloracetaldehyde generated by dechlorethylation of IF has been implicated in the pathogenesis of n e p h r ~p a t h y . ~
We did not detect an increase
π SIMILAR VOLUMES
## Abstract We describe 2 cases of proximal tubular defects induced by the administration of ifosfamide at a dosage of 6 g/m^2^/course over 2 days in children with a diagnosis of malignant mesenchymal tumors. This adverse effect could be minimized dividing dosage of the drug. However at present it
## BACKGROUND. The spectrum of side effects induced by chemotherapy includes skin hyperpigmentation. This is prone to occur following treatment with alkylating agents and doxorubicin. More recently, hyperpigmentation was discovered in patients treated exclusively with intra-arterial cisplatin and
## Background and objective: Cutaneous hyperpigmentations are well-documented, but nevertheless rare side-effects of high-dose or long-term minocycline therapy. the pigmental changes, may last for years, even though therapy has been abrogated. to date, no safe and effective therapy has been describ